GlassScriptPhysician profile
Aliese A Smith
NPI 1952689804
$5,271.34
in general payments reported to CMS, 2019-2025
31 companies · $547 in 2025
The $547 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $120 · 2021: $3,125 · 2022: $417 · 2023: $301 · 2024: $330 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,123.25 | 2021-2022 | |
| Shield Therapeutics INC | $395.99 | 2023-2025 | Accrufer |
| Myovant Sciences INC. | $259.88 | 2021-2022 | |
| Abbvie INC. | $204.79 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $192.41 | 2023-2025 | Myfembree |
| Biogen, INC. | $162.86 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $121.29 | 2022-2025 | Aptima, Thinprep 2000 Processor, Fluent Fluid Management System |
| Exeltis, USA INC. | $77.57 | 2019-2024 | Slynd |
| Organon LLC | $71.28 | 2023-2024 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $64.01 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $61.87 | 2019 | |
| Mayne Pharma Commercial LLC | $61.54 | 2025 | |
| Pfizer INC. | $53.90 | 2020-2024 | |
| Coopersurgical, INC. | $50.43 | 2019-2022 | |
| Exact Sciences Corporation | $44.92 | 2024-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.73 | 2019-2021 | |
| Therapeuticsmd, INC. | $23.54 | 2019 | |
| Lilly USA, LLC | $23.20 | 2024 | Zepbound |
| Mylan Pharmaceuticals INC. | $22.65 | 2019 | |
| Novo Nordisk INC | $20.97 | 2023 | Saxenda, Wegovy |
| Evofem Biosciences, INC. | $20.07 | 2021 | |
| Lupin INC. | $18.62 | 2020 | |
| Intra-Sana Laboratories | $18.12 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Medicem INC. | $17.86 | 2021 | |
| Duchesnay USA Incorporated | $15.46 | 2019 | |
| Currax Pharmaceuticals LLC | $13.97 | 2021 | |
| Millicent US INC | $13.96 | 2019 | |
| Channel Medsystems, INC. | $12.29 | 2025 | |
| Amgen INC. | $11.61 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliese Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.